A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Clinical trial NCT02908906 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02908906
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-21
- Primary completion
- 2023-11-17
- Enrollment
- 234
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.